Publication #7411
Reference
CEM/CMO/2021/016
Name
COVID therapeutic alert – interleukin-6 inhibitors (tocilizumab or sarilumab) for patients hospitalised due to COVID-19
Categories
Scottish Government
Drug Alerts
Organization
Scottish Government Health and Social Care Directorates
Keywords
NHS
SCOTLAND
DRUGS
SAFETY
RISKS
PHARMACEUTICAL INDUSTRY
DRUG THERAPY
PHARMACEUTICAL SERVICES
Description
Attaches a letter about the combined policy replacing previous separately published policies for sarilumab and tocilizumab respectively on 17 February 2021. A single UK Interim Clinical Commissioning Policy has now been published, recommending that equal consideration is given to two potential interleukin-6 (IL-6) inhibitor treatment options - tocilizumab or sarilumab - for adult patients (aged 18 years and older) hospitalised due to COVID-19 in accordance with the agreed criteria for onward transmission.
Contact Name
Contact Email
Contact Address
Contact Phone
Created
2021-09-13 00:00:00
Click to go back to homepage